Press Releases
2026
- Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
- Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
- Nuvectis Pharma To Participate in Upcoming Investor Conferences
- Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
- Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
- Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
- Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
- Nuvectis Pharma Announces Proposed Public Offering of Common Stock
- Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
- Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
- Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
2025
- Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
- Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
- CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
- Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
- Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
- Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
- Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
- Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900 Phase 1a Dose Escalation Study
- Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a Combination Partner with Leading Therapies
- Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
- Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
- Nuvectis Pharma to Participate in the 37th Annual Roth Conference
- Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves the Efficacy of the EGFR Inhibitors in Preclinical Models of EGFR Mutated NSCLC
- Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
- Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
- Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
- Nuvectis Pharma Announces Proposed Public Offering of Common Stock
2024
- Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
- Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
- Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
- Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
- Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
- Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
- Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
- Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
- Nuvectis Pharma to Present at the 36th Annual Roth Conference
- Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
- Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
- Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2023
- Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
- Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
- Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
- Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
- Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
- Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
- Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
- Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
- Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
- Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights
- Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
- Nuvectis Pharma Announces FDA Clearance of NXP900 IND
- Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights
- Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
- Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
- Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
- Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
- Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
- Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights
- Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
- Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®
- Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
2022
- FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
- Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights
- Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
- Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference
- Nuvectis Pharma Announces Formation of a Scientific Advisory Board
- Nuvectis Pharma Announces Positive Data for NXP800 in a Preclinical Model of ARID1a-Mutated Gastric Carcinoma
- Nuvectis Pharma, Inc. to Present at Upcoming Investment Conferences
- Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
- Nuvectis Pharma Announces Closing of Approximately $15.9 Million Private Placement
- Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
- Nuvectis Pharma Announces FDA Clearance of IND for NXP800
- Nuvectis Pharma Announces Positive Data for NXP900 in a Preclinical Model of Group 4 Medulloblastoma, A Type of Brain Cancer That Affects Predominantly Pediatric Patients
- Nuvectis Pharma to Present in the H.C. Wainwright Global Investment Conference
- Nuvectis Pharma, Inc. Reports First Quarter 2022 Financial Results and Business Highlights
- Nuvectis Pharma Recaps Poster Presentation Highlights for NXP900 at the 2022 American Association for Cancer Research (AACR) Conference
- Nuvectis Pharma Recaps Oral Presentation Highlights for NXP800 at the 2022 American Association for Cancer Research (AACR) Conference
- Nuvectis Pharma, Inc. Reports Fiscal Year 2021 Financial Results and Business Highlights
- Nuvectis Announces Upcoming Oral and Poster Presentations at the 2022 American Association for Cancer Research Meeting
- Update - Nuvectis Pharma to Participate in a Fireside Chat at the 34th Annual Roth Conference
- Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
- Nuvectis Pharma Announces Closing of $16,000,000 Upsized Initial Public Offering of Common Stock
- Nuvectis Pharma, Inc. Announces Pricing of $16,000,000 Upsized Initial Public Offering of Common Stock
2021
- Nuvectis Pharma Initiates Phase 1 Clinical Trial of NXP800
- Nuvectis Pharma In-Licenses Exclusive Worldwide Rights to a Novel SRC/YES1 Inhibitor (NXP900) from the University of Edinburgh, Scotland
- Nuvectis Pharma Raises $15 Million and In-Licenses Exclusive Worldwide Rights to Novel Selective HSF1 Pathway Inhibitor from the CRT Pioneer Fund